Formulary Search

Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

Off-label use.

Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

Capsules are an unlicensed product.

Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

Off-label use.

Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

Capsules are an unlicensed product.

Off-label use.

Initiation by a SABP specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

Capsules are an unlicensed product.

Initiation by a SABP specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

Haloperidol decanoate - administration under the shared-care LCS when prescribed in Primary Care.

See shared care document below

Haloperidol decanoate - where there is no LCS in place, the prescribing responsibility remains with SABP.

Secondary Care may prescribe for in-patients (on the instruction of a SABP specialist) and prescribing continued by SABP after discharge.

This product has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making a formulary application.

This product has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making a formulary application.

Acarizax - RSFT Immunology and specialist paediatricians only. Approved in over 18s only. Licensed in children over 12 years.

Acaroid - RSFT Immunology only

Lais sublingual tablets - RSFT Immunology only

As per NICE TA - for treating moderate to severe house dust mite allergic rhinitis in people 12 to 65 years

To be initiated at specialist allergy clinics only (locally at ASPH & RSFT) with at least 3 months prescribing before transfer to primary care.

Hydrocortisone sodium phosphate by intramuscular injection

Hydrocortisone sodium succinate by intramuscular injection.

Hydrocortisone sodium phosphate by intravenous injection

Hydrocortisone sodium succinate by intravenous injection.

Initial supply from the initiating Trust. Primary Care may prescribe replacement supplies for patients who have clear, written instructions and a management plan has been provided to the GP.

Hydrocortisone sodium phosphate by intramuscular injection - does NOT require reconstitution.

Initial supply from the initiating Trust. Primary Care may prescribe replacement supplies for patients who have clear, written instructions and a management plan has been provided to the GP.

Hydrocortisone sodium succinate by intramuscular injection. Comes in a powder that requires reconstitution (may be less suitable for rescue kits)

(MHRA drug safety update December 2018) https://www.gov.uk/drug-safety-update/hydrocortisone-muco-adhesive-buccal-tablets-should-not-be-used-off-label-for-adrenal-insufficiency-in-children-due-to-serious-risks

Recommended in NICE NG191 if dexamethasone is unsuitable

https://www.toxbase.org/

Initiation and 3 months of treatment to be provided by specilaist team before any requests for primary care prescribing.

500mg capsules.

Off-label use in Sickle Cell. Initiation and stabilisation (3 months) by the specialist team before any request for primary care prescribing.

Sickle Cell in paediatrics - on advice from tertiary centre.

Tablets are considerably more expensive than capsules which have been agreed for off-label use in Sickle Cell.

Prescribe on advice from specialist e.g. dietitian 

Off-label use. On advice from palliative care specialist team.